NVS
The pre-generic cleanup
Novartis is doing the classic corporate version of cleaning out the garage before the moving truck arrives: 427 jobs are getting cut in the U.S. this year, mostly in East Hanover, New Jersey, where the company’s U.S. HQ sits.
Why the chop? Entresto — Novartis’ blockbuster heart failure drug — is heading toward a loss of market exclusivity, and that’s not the kind of calendar reminder anyone at Big Pharma enjoys. The company is reshaping its cardiovascular commercial team as it shifts emphasis away from the old reliable and toward newer bets.
Follow the money, not the nostalgia
Entresto brought in $7.7 billion last year, which is a very fancy way of saying Novartis has a lot to lose when generics show up and start acting like the uninvited guests who stayed too long. The company also flagged pressure coming for Tasigna and Promacta/Revolade, both of which are nearing the end of their patent lives too.
To soften that blow, Novartis is pushing resources toward Leqvio and pipeline candidates like pelacarsen. In other words: less “defend the old castle,” more “build the next one before the moat dries up.”
Big picture
Layoffs are never a great look, but for investors they can also be a signal that management is trying to get ahead of a revenue cliff instead of waiting for it to hit like a truck. The real question now is whether Novartis can turn those cost cuts into enough growth from Leqvio and the pipeline to keep the story moving in the right direction.